Adaptimmune Therapeutics (ADAP) Competitors $0.60 +0.00 (+0.82%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ADAP vs. ORIC, TERN, VECT, TRML, PHAT, PROK, ATXS, DNA, ANNX, and HUMAShould you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include ORIC Pharmaceuticals (ORIC), Terns Pharmaceuticals (TERN), VectivBio (VECT), Tourmaline Bio (TRML), Phathom Pharmaceuticals (PHAT), ProKidney (PROK), Astria Therapeutics (ATXS), Ginkgo Bioworks (DNA), Annexon (ANNX), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Adaptimmune Therapeutics vs. ORIC Pharmaceuticals Terns Pharmaceuticals VectivBio Tourmaline Bio Phathom Pharmaceuticals ProKidney Astria Therapeutics Ginkgo Bioworks Annexon Humacyte ORIC Pharmaceuticals (NASDAQ:ORIC) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment. Do institutionals & insiders have more ownership in ORIC or ADAP? 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 5.6% of ORIC Pharmaceuticals shares are owned by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in ORIC or ADAP? Adaptimmune Therapeutics received 255 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 72.09% of users gave ORIC Pharmaceuticals an outperform vote while only 63.02% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes6272.09% Underperform Votes2427.91% Adaptimmune TherapeuticsOutperform Votes31763.02% Underperform Votes18636.98% Which has better valuation & earnings, ORIC or ADAP? ORIC Pharmaceuticals has higher earnings, but lower revenue than Adaptimmune Therapeutics. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-4.56Adaptimmune Therapeutics$175.04M0.88-$113.87M-$0.22-2.75 Is ORIC or ADAP more profitable? ORIC Pharmaceuticals has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. ORIC Pharmaceuticals' return on equity of -42.47% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -42.47% -38.86% Adaptimmune Therapeutics -25.43%-74.15%-15.09% Does the media refer more to ORIC or ADAP? In the previous week, ORIC Pharmaceuticals had 6 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 9 mentions for ORIC Pharmaceuticals and 3 mentions for Adaptimmune Therapeutics. ORIC Pharmaceuticals' average media sentiment score of 0.53 beat Adaptimmune Therapeutics' score of 0.04 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ORIC Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptimmune Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ORIC or ADAP? ORIC Pharmaceuticals currently has a consensus target price of $18.29, suggesting a potential upside of 122.72%. Adaptimmune Therapeutics has a consensus target price of $2.79, suggesting a potential upside of 360.82%. Given Adaptimmune Therapeutics' higher probable upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ORIC or ADAP? ORIC Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. SummaryORIC Pharmaceuticals and Adaptimmune Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAP vs. The Competition Export to ExcelMetricAdaptimmune TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$154.78M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-2.7546.7391.3417.19Price / Sales0.88411.851,116.63116.80Price / CashN/A182.1042.5837.86Price / Book3.563.894.794.78Net Income-$113.87M-$42.21M$120.07M$225.60M7 Day Performance4.28%-2.14%-1.90%-1.24%1 Month Performance-4.45%4.21%11.43%3.06%1 Year Performance27.97%18.40%30.59%16.50% Adaptimmune Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAPAdaptimmune Therapeutics1.9048 of 5 stars$0.60+0.8%$2.79+360.8%+37.1%$154.78M$175.04M-2.75449News CoverageORICORIC Pharmaceuticals3.6726 of 5 stars$8.45-0.8%$18.29+116.4%-3.8%$596.32MN/A-4.6880Insider TradeGap DownTERNTerns Pharmaceuticals4.2382 of 5 stars$6.97+3.6%$18.30+162.6%-6.8%$592.03M$1M-5.7040VECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030TRMLTourmaline Bio2.44 of 5 stars$22.34+2.4%$54.00+141.7%+8.7%$572.87MN/A-7.7344PHATPhathom Pharmaceuticals2.996 of 5 stars$8.35+5.8%$23.00+175.4%-9.3%$570.97M$680,000.00-1.48110PROKProKidney2.0358 of 5 stars$1.93+7.2%$4.50+133.8%-15.6%$561.45MN/A-3.553Gap DownATXSAstria Therapeutics2.0765 of 5 stars$9.78+2.7%$25.60+161.8%+58.0%$551.89MN/A-4.5630News CoveragePositive NewsDNAGinkgo Bioworks0.7475 of 5 stars$9.50+0.6%$4.58-51.8%N/A$546.06M$251.46M-0.721,218Positive NewsANNXAnnexon2.1152 of 5 stars$5.12+15.3%$15.80+208.6%+81.6%$545.76MN/A-4.9060Analyst ForecastNews CoverageGap DownHUMAHumacyte3.339 of 5 stars$4.23+3.2%$13.00+207.3%+69.3%$532.38M$1.57M-3.06150Analyst ForecastGap Up Related Companies and Tools Related Companies ORIC Alternatives TERN Alternatives VECT Alternatives TRML Alternatives PHAT Alternatives PROK Alternatives ATXS Alternatives DNA Alternatives ANNX Alternatives HUMA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADAP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAP Stock Alerts